Mirum Pharmaceuticals (MIRM) has just completed a zero coupon convertible note offering of $600 million due 2032, a financing move that can reshape its capital structure and influence how investors assess the stock.

Mirum’s recent zero coupon convertible note offering comes after a mixed stretch for the stock, with the share price up 26.32% year to date but down 8.24% over 90 days. The one year total shareholder return of 124.14% and five year total shareholder return of about 5x highlight strong long term gains, as sentiment now adjusts around the company’s larger funding base and upcoming conference appearances.

If you are assessing how this financing move fits into a broader set of healthcare opportunities, it can help to scan other rare disease and biotech names through our focused screener of 34 healthcare AI stocks

With Mirum now carrying a larger cash cushion, a zero coupon convertible over its head, strong recent shareholder returns and an analyst price target above the last close, you have to ask: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 24% Undervalued

Mirum’s most followed narrative pegs fair value at about $129.73 per share, which sits well above the recent $98.62 close and frames the recent financing against a higher long term target level.

The expanding addressable patient population for Mirum's therapies, especially with the increased recognition and diagnosis of later-onset PFIC through broader use of genetic testing and heightened disease awareness, is driving higher-than-expected patient volumes. This growing patient base is expected to directly contribute to sustained top-line revenue growth.

Want to see what sits behind that growth story? The narrative describes the relationship between revenue expansion, margin uplift and a rich future earnings multiple as one tight valuation case.

Result: Fair Value of $129.73 (UNDERVALUED)

However, the story hinges on successful trial readouts and regulatory decisions, so any clinical setback or reimbursement pushback could quickly challenge this underpriced narrative.

Next Steps

Seeing both optimism and concern in this story, it makes sense to move quickly, review the data yourself, and decide where you stand by checking the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Mirum has caught your attention, do not stop here. The next smart move is to widen your watchlist with stocks that match your style and risk comfort.

• Target potential mispricings by scanning 48 high quality undervalued stocks that may offer stronger fundamentals than their current share prices suggest.
• Build a steadier income stream by focusing on 10 dividend fortresses that combine higher yields with resilient payout histories.
• Prioritize capital preservation by reviewing 69 resilient stocks with low risk scores that score well on balance sheet strength and risk metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.